|
|
| | Brinzolamide-d5 Basic information |
| | Brinzolamide-d5 Chemical Properties |
| storage temp. | Refrigerator | | solubility | Ethanol | | form | Solid | | color | Crystalline |
| | Brinzolamide-d5 Usage And Synthesis |
| Description | Brinzolamide-d5 is intended for use as an internal standard for the quantification of brinzolamide by GC- or LC-MS. Brinzolamide is a potent inhibitor of carbonic anhydrase II (CAII) and CAIV (IC50s = 3.19 and 45.3 nM, respectively). It is selective for CAII and CAIV over CAI (IC50 = ~1,365 nM). Brinzolamide (30 mg/kg) reduces intestinal charcoal meal progression by 44% and prolongs pentobarbital sodium-induced sleep time by 35% in mice. Topical administration of brinzolamide (0.25, 0.5, and 1 mg/eye) reduces intraocular pressure in a rabbit model of spontaneous ocular hypertension. It also reduces intraocular pressure in a cynomolgus monkey model of argon laser trabeculoplasty-induced ocular hypertension. Formulations containing brinzolamide have been used in the treatment of glaucoma and ocular hypertension. | | Chemical Properties | Crystalline Solid | | Uses | Carbonic anhydrase inhibitor. Antiglaucoma agent. | | References | [1] PHD L D. Preclinical Overview of Brinzolamide[J]. Survey of ophthalmology, 2000, 44: Pages S119-S129. DOI: 10.1016/s0039-6257(99)00108-3 |
| | Brinzolamide-d5 Preparation Products And Raw materials |
|